Clinical Trials DEA Recreational Treatment 
NewsMunchies
NOVEMBER 12, 2021
In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinical trials underway in the U.S. We know such categorization is baseless and false. In a typical year in the U.S.
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. The state of the law on psychedelic substances is in flux. Id ; 21 CFR 312.1-10; 10; 312.80-88;
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
AUGUST 11, 2021
Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes.
Veriheal
APRIL 11, 2022
Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. Drug Enforcement Agency (DEA). Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials.
The Cannigma
MAY 1, 2023
Previously thought of as either a horse tranquilizer or a dissociative recreational party drug, ketamine has re-emerged as a promising therapeutic agent to treat pain, PTSD, depression, anxiety and more. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.
CannaMD
AUGUST 8, 2020
Hemp is often used in manufacturing; whereas marijuana serves a primarily medicinal/recreational purpose. For example, the DEA considers Schedule I drugs to have a “high potential for abuse and the potential to create severe psychological and/or physical dependence.” One more difference? CBD Scheduling Rule Change. What can CBD do?
Veriheal
AUGUST 31, 2020
Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.
Expert insights. Personalized for you.
90 
Let's personalize your content